Treprostinil (Remodulin) vs Treprostinil (Tyvaso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Treprostinil (Remodulin)
Marketed by United Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT06317805 (registry estimate)
No aligned efficacy figure on record for this race.
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Treprostinil (Remodulin): 4 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Treprostinil (Remodulin) | Treprostinil (Tyvaso) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | 440.8 ma,b,c NCT03055221 · Phase 4 · registry result, not featured evidence | 20 m @ 12wka,b,c NCT01268553 · Phase 4 · registry result, not featured evidence 1 other source trial230 m @ 12wk NCT00705133 · Phase 2 · registry result, not featured evidence |
| Dropout rate | n/a: no completion milestoned NCT03055221 · Phase 4 · registry result, not featured evidence | 11.3%e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 10%d NCT03055221 · Phase 4 · registry result, not featured evidence | —e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 87.5%d NCT03055221 · Phase 4 · registry result, not featured evidence | 7.8%e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | d abdominal discomfort 18.8% catheter site pain 18.8% cough 18.8% NCT03055221 · Phase 4 · registry result, not featured evidence | e cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: registered conditions differ.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
- ePopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Treprostinil (Remodulin)
Treprostinil (Tyvaso)
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Treprostinil (Remodulin)'s landscape · Treprostinil (Tyvaso)'s landscape